Fourth‐Generation HIV Rapid Tests: Enhanced Sensitivity and Reduced Diagnostic Window for HIV‐1 Primary Infection Screening
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70044 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Vincent Guiraud und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Virologie, INSERM, Institut Pierre Louis d' Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charl…. Hauptthemen laut MEDLINE: HIV Infections, Sensitivity and Specificity, HIV-1, HIV Core Protein p24. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This work was supported in part by the ANRS-MIE (Agence Nationale de Recherches sur le SIDA et les hepatitis virales-Maladies Infectieuses Emergentes) (Medical….
Abstract (Originalsprache)
As most HIV rapid tests (HRT) detect only HIV‐1/2 antibodies, their performance during primary HIV infection is poor. Determine HIV Early detect (Abbott) (Determine) is the only HRT with an HIV‐1 p24‐antigen detection, but the impact of this addition in shortening the diagnostic window remains unclear. A total of 183 HIV‐1 primary infection samples were tested using the HRTs Determine and ONE STEP anti‐HIV (1&2) Test (InTec Products) (One‐Step). The pre‐seroconversion subgroup was defined as p24‐antigen positivity without Western blot nor Liaison XL (fouth generation enzyme immunoassay with distinct signal for p24‐antigen and HIV‐1 antibody) HIV‐1 antibodies. Global sensitivity (95% CI) was 95% (91–97) for Determine versus 80% (74%–85%) for One‐Step (difference p = 1.38e−06). Pre‐seroconversion subgroup sensitivity was lower, at 71.9 (54.6%‐84.4%) for Determine and 9.7% (3.3%–24.9%) for One‐Step. Among the 45 samples with an HIV‐1 infection date, no HRT was reactive up to 2 weeks. Between 2 and 3 weeks, Determine sensitivity was 78% (45%–95%) versus 56% (27%–81%) for One‐Step. From 3 weeks to 1 month Determine sensitivity was 90% (62%–98%) and One‐Step 45% (21%–72%). The last negative sample occurred at 3 weeks for Determine versus 70–90 days for One‐Step. HRT with p24‐antigen detection significantly shortens the diagnostic window from approximatively 3 months to 1 month. HRTs should be used with caution in the first month after HIV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire de Virologie, INSERM, Institut Pierre Louis d' Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Sorbonne Université, Paris, France.
- INSERM UMR-S 1139, 3PHM, Université Paris cité, Paris, France.
ORCID-Profile: Vincent Guiraud
Förderung
- This work was supported in part by the ANRS-MIE (Agence Nationale de Recherches sur le SIDA et les hepatitis virales-Maladies Infectieuses Emergentes) (Medical…
Zitieren
APA
Guiraud, V., Naizet, A., Khan, H., Benhafoun, G., Hernandez, P., Piccin, L., Pichon, A., Leng, A. L., Yousfi, L., & Gautheret-Dejean, A. (2024). Fourth‐Generation HIV Rapid Tests: Enhanced Sensitivity and Reduced Diagnostic Window for HIV‐1 Primary Infection Screening. Journal of Medical Virology. https://doi.org/10.1002/jmv.70044
Vancouver
Guiraud V, Naizet A, Khan H, Benhafoun G, Hernandez P, Piccin L, et al. Fourth‐Generation HIV Rapid Tests: Enhanced Sensitivity and Reduced Diagnostic Window for HIV‐1 Primary Infection Screening. Journal of Medical Virology. 2024. doi:10.1002/jmv.70044
BibTeX
@article{Guiraud2024,
author = {Guiraud, Vincent and Naizet, Angèle and Khan, Habiba and Benhafoun, Ghizlane and Hernandez, Pierre and Piccin, Luigi and Pichon, Agnès and Leng, Ay Ling and Yousfi, Léna and Gautheret-Dejean, Agnès},
title = {Fourth‐Generation HIV Rapid Tests: Enhanced Sensitivity and Reduced Diagnostic Window for HIV‐1 Primary Infection Screening},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70044}
}
EUVIMED